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ABSTRACT
Objectives To study muscle biopsy tissue from patients
with juvenile dermatomyositis ( JDM) in order to test the
reliability of a score tool designed to quantify the
severity of histological abnormalities when applied to
biceps humeri in addition to quadriceps femoris.
Additionally, to evaluate whether elements of the tool
correlate with clinical measures of disease severity.
Methods 55 patients with JDM with muscle biopsy
tissue and clinical data available were included. Biopsy
samples (33 quadriceps, 22 biceps) were prepared and
stained using standardised protocols. A Latin square design
was used by the International Juvenile Dermatomyositis
Biopsy Consensus Group to score cases using our
previously published score tool. Reliability was assessed by
intraclass correlation coefﬁcient (ICC) and scorer agreement
(α) by assessing variation in scorers’ ratings. Scores from
the most reliable tool items correlated with clinical
measures of disease activity at the time of biopsy.
Results Inter- and intraobserver agreement was good or
high for many tool items, including overall assessment of
severity using a Visual Analogue Scale. The tool functioned
equally well on biceps and quadriceps samples. A modiﬁed
tool using the most reliable score items showed good
correlation with measures of disease activity.
Conclusions The JDM biopsy score tool has high inter-
and intraobserver agreement and can be used on both
biceps and quadriceps muscle tissue. Importantly, the
modiﬁed tool correlates well with clinical measures of
disease activity. We propose that standardised assessment
of muscle biopsy tissue should be considered in diagnostic
investigation and clinical trials in JDM.
INTRODUCTION
The idiopathic inﬂammatory myopathies are rare
complex chronic inﬂammatory disorders affecting
muscle, skin and other organs. The most common
childhood idiopathic inﬂammatory myopathy (onset
before 16th birthday)—juvenile dermatomyositis
( JDM)—has an incidence of 2–3 cases/million/
year.1 2 The rarity of JDM makes recognition and
assessment challenging for clinicians and histopathol-
ogists. Until now there has been no standardised
histological approach to the assessment of the
severity of abnormalities in muscle biopsy specimens
from patients with suspected JDM. The JDM Cohort
and Biomarker study collects clinical data and
samples, including biopsy material, from children
with myositis from across the UK and Ireland.3
The International Juvenile Dermatomyositis
Biopsy Consensus Group has previously designed
and tested a scoring tool for assessment of the
severity of pathological change in biopsy specimens
from patients with suspected or proven JDM.4 This
tool assesses features agreed to be characteristic of
JDM, organised into four domains (inﬂammatory,
vascular, muscle ﬁbre and connective tissue). The
tool also includes an overall score of severity,
scored by marking a Visual Analogue Score (histo-
pathologists’ VAS) (1.0–10.0 cm). If particular
items assessed within a score tool correlate well
with clinical features, disease course or response to
treatment, the tool would be a valuable addition to
the evaluation of this complex disease. A similar
approach to quantify features of renal allograft
rejection was reﬁned, validated and tested to
produce the Banff scoring system.5 Retrospective
studies of JDM biopsies have suggested that mor-
phological features may correlate with clinical
course but standardised scoring systems have not
been previously used.6 To our knowledge there are
no similar standardised tools available for assess-
ment of pathological features in muscle biopsies.
The aims of this study were to reassess the reliabil-
ity of the JDM score tool in quadriceps, including a
comparison with our previous results,4 and to assess
reliability of the tool when applied to biceps humeri,
since this muscle is regularly sampled in some
centres. To support the utility of the tool for multi-
centre studies we wished to determine the intraobser-
ver agreement of the tool elements. Finally, we
evaluated whether items of the score tool are asso-
ciated with clinical measures of disease severity.
PATIENTS AND METHODS
Patients and biopsy material
Patients were recruited in the UK (through the UK
JDM Cohort and Biomarker study) and Brazil.
Both studies had full approval from ethical review
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boards and were carried out according to the declaration of
Helsinki. Criteria for inclusion were that children had deﬁnite
or probable JDM according to the Bohan and Peter criteria,7
and biopsy material was available for research. All children had
disease duration of <12 months before biopsy and had their
biopsy sample taken before use of steroids or disease-modifying
agents such as methotrexate or other immunosuppressive
agents. A total of 55 cases were available: 33 from UK, 22 from
Brazil (table 1). UK muscle samples were all from the quadriceps
femoris (vastus lateralis): 11 of these were reported in a previ-
ous study.4 In this study those 11 were analysed only for the
correlation with clinical data. Brazil tissues were all from biceps
humeri. We have shown that biceps and quadriceps have subtle
differences in ﬁbre size, fast:slow ﬁbre ratio and capillary:ﬁbre
ratio, therefore the muscle source of biopsy tissue is an import-
ant consideration on assessment.9
In both cohorts, clinical data at disease onset, serum muscle
enzyme levels, erythrocyte sedimentation rate and muscle
strength measured by manual muscle testing on the Medical
Research Council (MRC) scale 0–5 were recorded.8
Complications, including calcinosis, skin ulceration, lung,
cardiac and gastrointestinal (GI) involvement, were assessed
before biopsy. In the UK cohort, data on the Childhood
Myositis Assessment Score (CMAS), an assessment of overall
strength and stamina10 as well as physicians global assessment
(PGA, range 0.0–10.0) were also available.11
Histology and immunohistochemistry
Muscle biopsy sampling, histological staining and immunohisto-
chemistry were carried out as described previously.4 Histological
staining included haematoxylin and eosin, Gomori’s trichrome,
ATPase pH 4.6 and pH 9.4, nicotinamide adenine dinucleotide
dehydrogenase-tetrazolium reductase and acid phosphatase. For
immunohistochemistry, primary antibodies used were: anti-
human CD3 (UCHT1), anti-human CD68 (KP1), anti-human
major histocompatibility complex (MHC) class I heavy chain
(W6/32), anti-human neonatal myosin (WB-MHCn) (all from
Novacastra, Newcastle-Upon-Tyne, UK) and anti-human CD31
( JC70A, 1/20) (Dako, Cambridgeshire, UK).
Scoring exercises
The International Working Group on JDM Biopsy previously
proposed a score tool for assessment of JDM biopsy, designed
using samples from quadriceps femori.4 In this study the same
group of experts reconvened to assess inter- and intraobserver
reliability of the tool, its reliability when used to score biceps
tissue samples and to test correlation between elements of the
score tool and clinical features. All validation and reliability data
were generated from 44 new cases not used in our previous
study. For the main scoring exercise to assess inter-observer reli-
ability, 11 quadriceps samples and 11 biceps samples were
selected to include cases in each group demonstrating a range of
features and severity ( judged by HV and JLH). The quadriceps
and biceps samples were allocated by a 11×11 Latin square
design for each group, as described previously.4
A further 22 additional biopsy samples (11 quadriceps, 11
biceps) were each assessed by ﬁve scorers, randomly assigned
using a separate partial Latin square design (11×5) for quadri-
ceps and biceps. Scorers did not know to which set of results
their scores would contribute. Data from 11 quadriceps cases
were available from our previous study.4 These data allowed
inclusion of all 55 cases in the ﬁnal analysis for association with
clinical features. To assess intraobserver agreement, eight quadri-
ceps cases were scored again by eight scorers in an 8×8 Latin
square, 3 days apart from the initial scoring exercise. For each
scoring exercise the full panel of stained sections was available
as above; scorers were aware of age at time of biopsy and the
muscle source of each biopsy.
Data analysis, statistics and decision on most informative
items
Data from the scoring exercises were analysed to provide two
summary measures, as used previously.4 We used an intraclass
correlation coefﬁcient (ICC) as a measure of reliability, and as a
Table 1 Patient demographics and clinical features at time of biopsy
Quadriceps (n=33) Biceps (n=22) p Value
Patient characteristic/clinical features
Age at biopsy (years), median (IQR) 6.2 (3.3, 10) 7.5 (6.0, 9.3) 0.37
Age at onset (years), median (IQR) 5.7 (3.3, 9.5) 7.1 (5.7, 9.1) 0.31
Gender, female, number (%) 21 (64) 17 (77) 0.36
Time between symptoms onset to biopsy (months), median (IQR) 3.0 (2.0, 6.5) 2.5 (1.9, 5.4) 0.17
Strength of knee extensors by MMT,* n (%) score 2 5 (21) 4 (18)
3 8 (33) 8 (36) 0.238
4 7 (29) 10 (46)
5 4 (17) 0 (0)
Strength of elbow flexion by MMT,* n (%) score 2 2 (9) 4 (18)
3 10 (43) 8 (36) 0.273
4 6 (26) 9 (41)
5 5 (22) 1 (5)
CMAS,† median (IQR) 23.5 (13.3–36.8) N/A N/A
PGA,‡ median (IQR) 5.9 (3.5–7.2) N/A N/A
Calcinosis, n (%) 0 (0) 6 (27) 0.002
Skin ulceration,** n (%) 4 (13) 3 (14) 0.903
Lung involvement,** n (%) 8 (25) 5 (23) 0.848
Cardiac involvement,** n (%) 0 (0) 2 (9) 0.161
Gastrointestinal involvement,** n (%) 10 (31) 9 (41) 0.465
*MMT, manual muscle testing using the Medical Research Council scale, possible scores from 0 to 5.8
**Data available on 32 of the 33 cases.
†CMAS, Childhood Myositis Assessment Score, range 0–53.
‡PGA, physicians global assessment, range 0.0–10.0.
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measure of scorer agreement we used the ratio of the estimates
of the SD attributable to the scorer:the SD attributable to the
cases (α).11 The ICC and α value for each domain and each
item were used to classify the data as good, good* or poor.4 11
Items reaching an ICC>0.6 were considered to have high reli-
ability while items with an α score<0.4 had high agreement.
Where both reliability and agreement were high (ICC>0.6,
α<0.4), the item was classiﬁed as good; where either reliability
or agreement were high, but not both, performance of the item
was classiﬁed as good*. Where agreement and reliability were
low (ICC<0.6, α>0.4), the item was classiﬁed as poor. In the
intrarater exercise we calculated proportional agreement (pA;
the number of exact agreements of score divided by the number
of biopsies (n=8)) achieved by each scorer and for each item of
the tool. The median (and range) pA across all scorers for each
element of the tool is reported.12
To explore associations between clinical measures of disease
severity and tool items we used the modal score for each item in
the tool, with the exception of domain totals for which we used
the median values. Examination of these associations was
restricted to tool items which consistently exhibited good* or
good rating. Speciﬁcally, if they achieved good or good* in our
original scoring exercise4 and in both the 11×11 scoring exer-
cises conducted for this study, they were considered ‘informative
items’ and suitable for further analysis. Comparisons of ordered
categorical and binary variables (eg, MRC score, presence/
absence of skin ulceration, biopsy score tool items) were com-
pared between biopsy groups using Pearson’s χ2 test or Fisher’s
exact test, as appropriate. Age at onset, age at biopsy, time to
biopsy, histopathologists’ VAS and modiﬁed domain total scores
were compared using the Mann–Whitney U test.
The scores for the informative items, modiﬁed domain total
scores and histopathologists’ VAS were assessed for associations
with measures of muscle strength by calculating the Spearman’s
rank correlation coefﬁcient and conducting a test of independ-
ence. Pearson’s χ2 test or Fisher’s exact test were used to assess
whether scores for informative items were associated with the
presence of periungual erythema, skin ulceration, lung or GI
involvement. The Kruskal–Wallis test was used to assess whether
the modiﬁed domain total scores were associated with the pres-
ence of periungual erythema, skin ulceration, lung or GI
involvement. This test was also used to assess whether the
scores for the six informative items were associated with PGA
or CMAS in the UK cohort only. Spearman’s rank correlation
coefﬁcient was used to assess correlation between modiﬁed
domain total scores and PGA, modiﬁed domain total scores and
CMAS, histopathologists’ VAS and PGA and CMAS. All
p values reported are unadjusted for multiple testing.
RESULTS
Clinical data
Fifty-ﬁve patients with JDM (38 female, 17 male) were included
in this study. Table 1 shows the patient demographic and clinical
data. Patients had a median age at onset of 6.42 years (IQR 4.04–
9.13) and median disease duration of 3.0 months (IQR 2–6) at
time of biopsy. There were no signiﬁcant differences in age at
biopsy, duration of disease before biopsy or clinical severity
between the two groups of patients, with one exception: at the
time of biopsy, the Brazil cohort had six (27%) cases with calci-
nosis, while the UK cohort had none (p=0.002). Proximal
muscle strength as measured by manual muscle testing did not
differ between the two groups. CMAS and PGA data were avail-
able only from the UK cohort.
Score tool reliability
The score tool and accompanying instructions are shown in
online supplementary table S1.4 Data on score tool reliability
were generated from 22 cases (11 quadriceps, 11 biceps), all
new cases compared with our previous study.4 Overall scores for
inﬂammatory and muscle ﬁbre domains, as well as several items
from each of these domains and severity assessment by histo-
pathologists, reached high reliability for both quadriceps and
biceps samples (table 2). These items were also reliable in our
previous study.4 Intrarater agreement, assessed by pA, was sub-
stantial or better (>0.6) in all but one element. The median pA
was ≥75% for all the informative items (see online supplemen-
tary data, table S2).
Items that can be reliably assessed by the same observer on
different occasions and different observers will be useful in
future studies. Therefore we limited further analysis to inform-
ative items—that is, those that were the most reliable, shown in
bold in table 2. Two of these, overexpression of MHC protein
on muscle ﬁbres and infarction, had an α score of 0 indicating
high agreement, but low variability since they were either always
abnormal (MHC overexpression) or very rarely seen (infarc-
tion). These items were excluded from the modiﬁed score tool.
Selection of an element for further analysis depended on the
performance of that element rather than the importance of the
pathological feature for diagnostic purposes. Representative
examples of items selected for inclusion in the modiﬁed score
tool, from both biceps and quadriceps biopsies, are shown in
ﬁgure 1.
Association with disease severity measures
We reasoned that a modiﬁed score tool containing the most reli-
able items would be an appropriate instrument to investigate
associations with clinical measures of disease. The most reliable
items fell into two domains of the score tool: inﬂammatory and
muscle ﬁbre. Using these items, a modiﬁed total score range was
calculated for each of these domains. Scores for these informative
items, modiﬁed domain total scores and overall histopathologists’
VAS score data were analysed for all 55 cases (table 3).
Comparison of the number of biopsies scoring high or low for
each of these items suggested that the biceps samples showed
more severe pathology than quadriceps, with differences
between scores for the modiﬁed muscle ﬁbre domain total, two
individual items in the muscle ﬁbre domain, as well as a signiﬁ-
cantly higher histopathologists’ VAS for severity in biceps com-
pared with quadriceps (table 3).
There was evidence to suggest that measures of weakness were
associated with biopsy scores for all of the informative items, the
modiﬁed total domain scores and the histopathologists’ overall
severity score (table 4). Speciﬁcally, a higher modiﬁed total for
both domains was strongly associated with elbow ﬂexor strength
score as assessed by the MRC scale (0–5), r=−0.59 p<0.0001:
r=−0.60 and p<0.0001 for inﬂammatory and muscle ﬁbre
domains, respectively. Within the muscle ﬁbre domain substantial
correlations were seen between the neonatal myosin positivity
and both measures of strength (r=−0.57 p<=0.001). The histo-
pathologists’ VAS was also signiﬁcantly associated with measures
of weakness (table 4). No associations were found between the
six informative items and periungual erythema, skin ulceration,
lung or GI involvement (data not shown).
For quadriceps biopsies, where data on PGA and CMAS were
also available, PGA was associated with the biopsy score for the
informative items in the inﬂammatory domain (CD3+ endomy-
sial, CD3+ perimysial and CD68+ endomysial) and two items
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in the muscle ﬁbre domain (neonatal myosin and perifascicular
regeneration/degeneration/necrosis). Both modiﬁed domain total
scores were moderately correlated with PGA, with the inﬂam-
matory domain showing a stronger relationship. In all of the
above the direction of the association was as expected; a higher
biopsy feature score was associated with higher PGA. Both
modiﬁed total muscle ﬁbre and modiﬁed total inﬂammatory
domains were weakly correlated with CMAS. Details of these
correlations are shown in online supplementary table S3.
DISCUSSION
These data provide the ﬁrst validation of a histological score
tool estimating severity in JDM, much needed in this uncom-
mon but potentially devastating autoimmune childhood disease.
The tool is designed to measure histological severity using semi-
quantitative assessment of histological features, rather than to
diagnose the condition. This study extends our earlier ﬁndings
and demonstrates the reliability of the tool, with low inter- and
intraobserver variability. Importantly, the most reliable items of
the scoring system correlate well with measures of clinical
disease activity.
Our study used cases from two different countries, where the
muscle used for diagnostic biopsy differs. Although all biopsies
were taken early in disease course, calcinosis was more common in
cases from Brazil, perhaps reﬂecting disease severity in that
cohort,13 and biceps biopsy samples were also scored as more
severe in several items (table 3). As biceps samples were not avail-
able from UK cases, nor quadriceps tissue from Brazilian cases and
no case had samples from both muscles, it was not possible to test
how the site of the biopsy affects pathological change. It is also
possible that there are other differences between the groups of
patients, related not to biopsy site, but to differences in clinical
care, ethnicity or environment. Despite these potential confoun-
ders we found that the score tool functioned equally well on
biceps and quadriceps tissue, and the same score items were the
most reliable for both sample sets. By incorporating biceps
samples we have generated data suggesting that the score tool can
be applied to a muscle other than quadriceps. This provides conﬁ-
dence for inclusion in future studies of centres whose biopsy site is
routinely either biceps or quadriceps.
After identifying morphological features that proved reliable
between different assessors and different muscles, we showed
that these items were moderately or strongly correlated with
muscle strength, and with the overall PGA and CMAS, where
available. Thus the score tool appears to correlate well with
muscle disease activity. A limitation to this analysis is that skin
score data were not available on a sufﬁciently large number of
cases to compare biopsy assessment with skin disease activity.
The adoption of agreed protocols for histological assessment
of tissue has provided important progress in other diseases,
especially in conditions where semiquantitative analysis of spe-
ciﬁc features has been found to correlate with clinical severity
and hence inﬂuence management. For example the Banff
scoring of renal pathology is widely used to quantify allograft
rejection, in trials of anti-rejection drugs and in clinical practice.
This system has been reﬁned, altered, validated and tested in
several stages.5 Similarly, the BrainNet Europe consortium has
tested, standardised and validated assessment of features such as
Table 2 Results of intraclass coefficient (ICC) and measure of agreement (α score) for both sets of 11 biopsies* scored in the 11×11 scoring
exercises, with 95% CIs†
Domain
Quadriceps Biceps
ICC α Score ICC α Score
Inflammatory domain 0.81 (0.61 to 0.93) 0.38 (0.19 to 0.74) 0.80 (0.62 to 0.93) 0.34 (0.16 to 0.68)
CD3+ endomysial infiltration 0.72 (0.53 to 0.89) 0.15 (0.0 to 0.39) 0.74 (0.56 to 0.90) 0.26 (0.08 to 0.54)
CD3+ perimysial infiltration 0.61 (0.39 to 0.83) 0.31 (0.05 to 0.67) 0.75 (0.57 to 0.91) 0.20 (0 to 0.44)
CD3+ perivascular infiltration 0.58 (0.37 to 0.82) 0.41 (0.14 to 0.84) 0.58 (0.37 to 0.82) 0.44 (0.17 to 0.90)
CD68+ endomysial infiltration 0.66 (0.45 to 0.86) 0.40 (0.17 to 0.82) 0.62 (0.41 to 0.84) 0.22 (0.0 to 0.53)
CD68+ perimysial infiltration 0.48 (0.27 to 0.76) 0.59 (0.24 to 1.2) 0.79 (0.63 to 0.93) 0.18 (0.0 to 0.40)
CD68+ perivascular infiltration 0.40 (0.20 to 0.70) 0.83 (0.37 to 1.65) 0.33 (0.15 to 0.63) 0.97 (0.43 to 0.93)
Vascular domain 0.48 (0.27 to 0.76) 0.57 (0.23 to 1.2) 0.49 (0.28 to 0.76) 0.54 (0.21 to 1.10)
Capillary dropout 0.39 (0.20 to 0.68) 0.73 (0.29 to 1.47) 0.26 (0.11 to 0.55) 0.95 (0.34 to 2.0)
Arterial abnormality 0.40 (0.21 to 0.70) 0.56 (0.18 to 1.18) 0.42 (0.23 to 0.71) 0.52 (0.15 to 1.09)
Infarction 0 (0 to 0.16) 0 0.42 (0.22 to 0.71) 0.34 (0 to 0.80)
Muscle fibre domain 0.80 (0.63 to 0.93) 0.25 (0.10 to 0.52) 0.86 (0.71 to 0.95) 0.26 (0.12 to 0.52)
MHC class I overexpression 0.31 (0.14 to 0.62) 0.28 (0.0 to 0.82) 0 (0 to 0.14) 0
Perifascicular atrophy 0.63 (0.43 to 0.85) 0.28 (0 to 0.61) 0.76 (0.58 to 0.910 0.29 (0.11 to 0.59)
Neonatal myosin 0.83 (0.68 to 0.94) 0 (0 to 0.20) 0.88 (0.76 to 0.96) 0.06 (0 to 0.20)
Fibre atrophy: non-perifascicular 0.28 (0.13 to 0.59) 0.83 (0.29 to 1.72) 0.32 (0.15 to 0.62) 0.76 (0.26 to 1.56)
Regeneration/degeneration/necrosis: perifascicular 0.58 (0.36 to 0.82) 0.39 (0.12 to 0.81) 0.84 (0.70 to 0.94) 0.18 (0.05 to 0.30)
Regeneration/degeneration/necrosis: non-perifascicular 0.51 (0.30 to 0.78) 0.38 (0.05 to 0.81) 0.60 (0.38 to 0.83) 0.50 (0.22 to 1.0)
Internal myonuclei 0.63 (0.42 to 0.85) 0.33 (0.09 to 0.69) 0.32 (0.15 to 0.63) 0.63 (0.16 to 1.34)
Connective tissue domain 0.34 (0.16 to 0.64) 0.74 (0.27 to 1.52) 0.41 (0.21 to 0.70) 0.62 (0.23 to 1.28)
Any endomysial fibrosis 0.35 (0.17 to 0.65) 0.66 (0.22 to 1.38) 0.32 (0.15, 0.63) 0.60 (0.11 to 1.39)
Any perimysial fibrosis 0.19 (0.07 to 0.47) 1.03 (0.26 to 2.17) 0.36 (0.18 to 0.66) 0.70 (0.26 to 1.44)
Histopathologists’ Visual Analogue Score for severity 0.77 (0.60 to 0.91) 0.20 (0.03 to 0.44) 0.87 (0.74 to 0.96) 0.19 (0.08 to 0.40)
*All 22 cases used to generate these data were new cases, distinct from the previous study.4
†ICC>0.6 indicates high reliability, α score <0.4 indicates high agreement.
‡Items shown in bold reached good or good*, as detailed in text.
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α-synuclein immunoreactive structures and amyloid β, in neuro-
degenerative diseases.14 15
In JDM, some evidence suggests that histopathological fea-
tures indicative of vasculopathy correlate with more aggressive
disease,16 or that features of vasculopathy and necrosis may
predict chronicity.6 However, those studies did not include
biopsy analysis by a large group of observers and it is therefore
difﬁcult to assess how readily they would translate to multiple
Figure 1 Features of dermatomyositis including the informative score tool items selected for the modiﬁed score tool, illustrated in a quadriceps
biopsy (A, C, D, F and H) and in a biceps biopsy (B, E, G and I). Perivascular inﬂammation was seen, often with a perimysial localisation (A and B,
arrows indicate vessels). Perifascicular ﬁbre atrophy was a feature of some biopsies, and other ﬁbre abnormalities including basophilia, indicating
regeneration, were often more prominent in perifascicular regions (B, double arrow). CD3 immunoreactive T cells were present in the perimysium
(C and E, arrows) and also the endomysium (D, arrow). Macrophage inﬁltrates were identiﬁed by CD68 immunohistochemistry in the endomysium
(F and G, arrow) and also around vessels (G, double arrow). Neonatal myosin expression could often be seen to have a characteristic perifascicular
pattern (H and I). (A and B) haematoxylin and eosin; (C, D and E) CD3 immunohistochemistry; (F and G) CD68 immunohistochemistry; (H and I)
neonatal myosin immunohistochemistry. Bars represent: 50 mm in A, B, C, E and G; 25 mm in D and F; 100 mm in H; 260 mm in I.
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centres. One difﬁculty with assessment of rare diseases is ensur-
ing adequate training for pathologists who may encounter only
occasional cases. Online image databases might assist with this
problem. To circumvent technical barriers and ensure that the
tool is robust we have chosen to select features that were most
reliable between a group of assessors and used standard, widely
available, histopathological stains in preparation of sections.
A limitation of our study is the large number of hypothesis
tests conducted to evaluate associations between biopsy features
and measures of disease severity. This is likely to result in a high
false discovery rate and therefore the reported p values must be
interpreted with caution. However, the consistency of the data
for associations with muscle strength, warrant consideration and
further investigation.17 18
Long-term prospective studies are needed to test whether the
JDM muscle score tool (and which items of the tool), using tissue
obtained at the time of diagnosis, correlates well with disease course,
treatment response or disease complications. It will be interesting to
test how speciﬁc aspects of the tool correlate with more recently
reported biomarkers, including the type I interferon gene signature,
serum chemokine score or plasmacytoid denritic cells.19–22
In conclusion we have shown for the ﬁrst time that a modiﬁed
JDM biopsy score tool has high inter- and intraobserver agree-
ment and can be used on both biceps and quadriceps muscle
tissue. We suggest that inclusion of this simple, semiquantitative
measure into routine diagnostic investigation and clinical trials
in children with JDM, should facilitate a more standardised
comparison of cases between studies and different centres.
Table 3 Comparison of tool scores for the informative items used in clinical correlation analysis, in quadriceps and biceps biopsies
Domain Quadriceps (n=33) Biceps (n=22) p Value
Inflammatory domain Tool score n (%) n (%)
CD3+ endomysial infiltration 0 11 (33) 11 (50)
1 14 (42) 9 (41) 0.27
2 8 (24) 2 (9)
CD3+ perimysial infiltration 0 11 (33) 12 (55)
1 12 (36) 7 (32) 0.22
2 10 (30) 3 (14)
CD68+ endomysial infiltration 0 2 (6) 3 (14)
1 8 (24) 5 (23) 0.63
2 23 (70) 14 (64)
Inflammatory domain total (modified), median (IQR) Possible range 0–6 4 (1.5, 5) 2.5 (1, 4) 0.15
Muscle fibre domain
Perifascicular atrophy 0 22 (67) 6 (27)
1 0 (0) 1 (5) 0.01
2 11 (33) 15 (68)
Neonatal myosin 0 9 (27) 8 (36)
1 24 (73) 14 (64) 0.48
Regeneration/degeneration/necrosis: perifascicular 0 20 (61) 6 (27)
1 2 (6) 1 (5) 0.04
2 11 (33) 15 (68)
Muscle fibre domain total (modified), Possible range 0–5 2 (0, 4) 5 (1, 5) 0.01
Histopathologists’ VAS, median (IQR) Range 0–10 3.3 (1.1, 5.9) 6.1 (2.2, 7.5) 0.023
VAS, Visual Analogue Score.
Table 4 Associations between manual muscle testing (MMT) and items of the modified score tool for the combined cohort (London and
Brazil)
Domain and item
Knee extensor MMT Elbow flexion MMT
r* p Value† r* p Value†
Inflammatory domain
CD3+ endomysial infiltration −0.40 0.006 −0.44 0.003
CD3+ perimysial infiltration −0.40 0.007 −0.41 0.006
CD68+ endomysial infiltration −0.53 0.002 −0.62 <0.001
Inflammatory domain total (modified) −0.56 0.001 −0.59 <0.0001
Muscle fibre domain
Perifascicular atrophy −0.30 0.040 −0.40 0.006
Neonatal myosin −0.57 0.001 −0.57 <0.001
Regeneration/degeneration/necrosis: perifascicular −0.38 0.009 −0.53 0.002
Muscle fibre domain total (modified) −0.45 0.002 −0.60 <0.0001
Histopathologists’ Visual Analogue Score for severity −0.45 0.002 −0.62 <0.0001
*Spearman’s rank correlation coefficient.
†For test of independence.
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